Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade F 26.85 0.45% 0.12
MYL closed up 0.45 percent on Thursday, April 18, 2019, on 68 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MYL trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 0.45%
Oversold Stochastic Weakness -0.81%
BB Squeeze Ended Range Expansion -0.30%
Down 3 Days in a Row Weakness -0.30%
Oversold Stochastic Weakness -0.30%

Older signals for MYL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceutical Industry In China Pharmaceuticals Policy Active Pharmaceutical Ingredients Hiv/Aids Generic Drug Healthcare Institutions Disorder Generic Pharmaceutical Products Pharmaceutical Wholesalers Drug Manufacturers Injectable Products
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.5
52 Week Low 26.0
Average Volume 5,429,690
200-Day Moving Average 32.6504
50-Day Moving Average 28.5262
20-Day Moving Average 27.5905
10-Day Moving Average 27.13
Average True Range 0.68
ADX 19.92
+DI 13.3408
-DI 25.7605
Chandelier Exit (Long, 3 ATRs ) 27.26
Chandelier Exit (Short, 3 ATRs ) 28.48
Upper Bollinger Band 28.839
Lower Bollinger Band 26.342
Percent B (%b) 0.2
BandWidth 9.050217
MACD Line -0.4331
MACD Signal Line -0.3929
MACD Histogram -0.0402
Fundamentals Value
Market Cap 14.4 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 21.65
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.77
Resistance 3 (R3) 27.77 27.48 27.61
Resistance 2 (R2) 27.48 27.24 27.47 27.56
Resistance 1 (R1) 27.16 27.10 27.32 27.16 27.51
Pivot Point 26.87 26.87 26.95 26.86 26.87
Support 1 (S1) 26.55 26.63 26.71 26.55 26.19
Support 2 (S2) 26.26 26.49 26.25 26.14
Support 3 (S3) 25.94 26.26 26.09
Support 4 (S4) 25.94